List of Excipients in Branded Drug BAXDELA

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Melinta Therapeutics LLC	BAXDELA	delafloxacin meglumine	70842-101	ANHYDROUS CITRIC ACID	2031-06-19
Melinta Therapeutics LLC	BAXDELA	delafloxacin meglumine	70842-101	CELLULOSE, MICROCRYSTALLINE	2031-06-19
Melinta Therapeutics LLC	BAXDELA	delafloxacin meglumine	70842-101	CROSPOVIDONE	2031-06-19

BAXDELA Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: September 10, 2026

BAXDELA is delafloxacin, a fluoroquinolone antibacterial marketed by Melinta Therapeutics. Its formulation strategy uses a conventional immediate-release tablet and an intravenous lyophilized product built around sulfobutyl ether beta-cyclodextrin sodium, a solubilizing excipient. The strongest commercial opportunities are generic oral delafloxacin, hospital-focused IV-to-oral treatment pathways, excipient-enabled reformulations, and supply-chain alternatives for the injectable product. The principal constraints are fluoroquinolone safety warnings, limited market size relative to broader antibiotics, and competition from established agents such as vancomycin, linezolid, ceftaroline, and newer anti-MRSA products.

What is BAXDELA and how is it formulated?

BAXDELA contains delafloxacin, administered either as tablets or as an intravenous infusion. The FDA-approved strengths are 450 mg tablets and 300 mg intravenous vials. The drug is indicated in adults for acute bacterial skin and skin-structure infections and community-acquired bacterial pneumonia caused by susceptible organisms, including relevant Gram-positive and Gram-negative pathogens (FDA, 2023).

Product	Strength	Dosage form	Main excipient strategy
BAXDELA tablets	450 mg	Immediate-release film-coated tablet	Standard direct-compression excipient system
BAXDELA injection	300 mg/vial	Lyophilized powder for IV infusion	Cyclodextrin-based solubilization and lyophilized cake
Active moiety	Delafloxacin meglumine	Fluoroquinolone antibacterial	Salt form supports aqueous handling and formulation

The tablet formulation uses microcrystalline cellulose, crospovidone, povidone, colloidal silicon dioxide, and magnesium stearate. The film coating contains polyvinyl alcohol, titanium dioxide, polyethylene glycol, and talc. These ingredients support tablet compression, disintegration, flow, lubrication, and coating performance without relying on a novel oral delivery platform.

The injectable formulation contains sulfobutyl ether beta-cyclodextrin sodium and mannitol. Sulfobutyl ether beta-cyclodextrin sodium improves aqueous solubility of the delafloxacin salt. Mannitol supports the physical structure of the lyophilized cake and contributes to reconstitution performance. Hydrochloric acid and sodium hydroxide may be used for pH adjustment during manufacture (FDA, 2023).

What excipients are protected by the BAXDELA formulation?

The commercial value of BAXDELA's excipient system is greater in manufacturing and regulatory execution than in direct composition-of-matter exclusivity.

Oral tablet excipients

The tablet excipients are widely used pharmaceutical materials:

• Microcrystalline cellulose for bulk and compaction.
• Crospovidone for rapid disintegration.
• Povidone as a binder.
• Colloidal silicon dioxide as a glidant.
• Magnesium stearate as a lubricant.
• Polyvinyl alcohol, polyethylene glycol, talc, and titanium dioxide for film coating.

A generic applicant can generally use the same excipients or alternative pharmaceutically acceptable excipients, subject to product quality, bioequivalence, and regulatory requirements. The branded formulation may still create practical barriers if the reference product has narrow dissolution specifications, complex solid-state behavior, or process-sensitive tablet attributes.

Intravenous excipients

The injectable product presents a more meaningful formulation barrier. Delafloxacin has limited aqueous handling characteristics, and sulfobutyl ether beta-cyclodextrin sodium is used to maintain a suitable concentration for IV administration. The formulation must also control:

• Reconstitution time.
• Solution clarity.
• pH.
• Osmolality.
• Particulate burden.
• Container-closure compatibility.
• Stability after reconstitution and dilution.
• Compatibility with common infusion solutions and administration sets.

The use of sulfobutyl ether beta-cyclodextrin sodium creates a potential supply-chain dependency. Qualified suppliers, pharmaceutical-grade specifications, residual solvent controls, endotoxin limits, and manufacturing capacity can affect cost and continuity of supply.

What commercial opportunities exist for BAXDELA excipients?

Generic oral delafloxacin

The largest near-term excipient opportunity is an oral generic. The tablet formulation does not require a highly specialized delivery system. A manufacturer could pursue:

1. A conventional immediate-release tablet using the same functional excipient classes.
2. A lower-cost coating system with equivalent performance.
3. A tablet manufacturing process optimized for high-speed compression.
4. A dual-source excipient strategy to reduce supply risk.
5. An authorized or licensed formulation using existing delafloxacin manufacturing know-how.

The main development work would involve assay and content uniformity, dissolution across pH conditions, impurity control, polymorph or salt-form control, and comparative bioequivalence.

Injectable generic or 505(b)(2) product

The IV product offers a higher technical barrier and potentially higher margin. Opportunities include:

• A generic lyophilized vial.
• A ready-to-dilute presentation.
• A premixed infusion bag.
• A smaller-volume vial for outpatient parenteral antimicrobial therapy.
• A dual-chamber container that separates drug and diluent until administration.
• A room-temperature-stable presentation.
• A formulation with reduced reconstitution time.

A premixed bag could have hospital value if it reduces pharmacy compounding, handling, and preparation errors. The tradeoff is increased stability, container compatibility, extractables and leachables, and cold-chain or room-temperature stability work.

Excipient supply and dual sourcing

Sulfobutyl ether beta-cyclodextrin sodium is the most commercially differentiated excipient in the BAXDELA formulation. Suppliers can compete through:

• Qualified alternative grades.
• Lower endotoxin specifications.
• Improved batch-to-batch consistency.
• Shorter lead times.
• Regional manufacturing.
• Regulatory support packages.
• Supply agreements with generic delafloxacin developers.

The opportunity is stronger for injectable products than tablets because excipient substitution can affect solubility, impurity profiles, reconstitution, and stability.

How does BAXDELA compare with competing antibiotics?

BAXDELA competes in acute bacterial skin infections and community-acquired bacterial pneumonia. Its market position depends on pathogen coverage, route of administration, local resistance patterns, safety restrictions, hospital protocols, and total treatment cost.

Product	Primary commercial distinction	Formulation opportunity
BAXDELA, delafloxacin	Oral and IV fluoroquinolone with MRSA activity	Generic tablet, IV lyophilized product, premix
Zyvox, linezolid	Oral bioavailability and established MRSA use	Low technical barrier for oral generic competition
Teflaro, ceftaroline	IV cephalosporin with MRSA activity	Injectable manufacturing and hospital contracting
Vancomycin	Broad hospital use and low acquisition cost	Formulation competition is limited; administration burden remains
Dalvance, dalbavancin	Long-acting IV dosing	Premium convenience and extended-interval delivery
Orbactiv, oritavancin	Single-dose IV treatment for selected infections	High convenience but narrower commercial positioning

BAXDELA's oral and IV availability can reduce the need for separate agents during hospitalization and discharge planning. The economic value is highest when the prescriber wants to continue the same active ingredient after an IV start, provided the patient can absorb oral therapy and the organism is susceptible.

What FDA regulatory status does BAXDELA have?

The FDA approved BAXDELA tablets and injection in June 2017 for acute bacterial skin and skin-structure infections. The agency later expanded the indication to community-acquired bacterial pneumonia in adults (FDA, 2017; FDA, 2019).

FDA milestone	Date
Initial approval for acute bacterial skin and skin-structure infections	June 2017
Community-acquired bacterial pneumonia indication	2019
Approved adult dosage forms	450 mg tablet; 300 mg IV vial

BAXDELA carries class-related fluoroquinolone warnings involving tendinitis and tendon rupture, peripheral neuropathy, central nervous system effects, and exacerbation of myasthenia gravis. Product development and commercial messaging must account for these warnings and the FDA's position that fluoroquinolones should generally be reserved for certain conditions when alternative treatment options exist because of serious adverse reactions (FDA, 2023).

What patents protect BAXDELA and when does exclusivity end?

BAXDELA's protection is likely distributed across delafloxacin composition, salt forms, crystalline or solid-state forms, formulations, manufacturing processes, and methods of treatment. The commercial analysis should separate these categories because expiry of one patent does not necessarily eliminate all formulation or method-of-use barriers.

The most important practical distinction is between:

• Core active-ingredient or chemical patents.
• Delafloxacin meglumine or salt-form patents.
• Solid-state and crystalline-form patents.
• IV solubilization and lyophilization patents.
• Method-of-use patents for specified infections.
• Regulatory exclusivity and patent listings in the FDA Orange Book.

The Orange Book should be reviewed for current listed patents, pediatric exclusivity, and any patent-term extension. Patent expiry cannot be inferred reliably from the brand launch date alone. A patent's expiration date may depend on terminal disclaimers, patent-term adjustment, patent-term extension, or later-issued continuation patents (FDA, 2024).

For a generic applicant, the relevant pathway is typically an ANDA with Paragraph IV certification against listed patents, unless the applicant waits until patent expiry or relies on a non-infringing formulation and certification strategy. The commercial launch date would depend on patent litigation, any 30-month stay, first-applicant status, settlement terms, and the scope of any court judgment.

What Paragraph IV and litigation risks affect generic BAXDELA?

A delafloxacin generic faces several possible challenges:

1. Chemical and salt-form risk. The applicant must establish that its active ingredient and salt form do not infringe enforceable claims.
2. Solid-state risk. Different polymorphs, hydrates, or amorphous forms may create separate patent issues.
3. Injectable formulation risk. A formulation using sulfobutyl ether beta-cyclodextrin sodium may implicate formulation or process claims.
4. Method-of-use risk. Label carve-outs may be required if listed claims cover only a subset of indications.
5. Manufacturing risk. Process patents may affect synthesis, purification, crystallization, or lyophilization.
6. Regulatory exclusivity risk. Any remaining statutory exclusivity can delay approval independently of patents.

The strongest generic strategy is generally a differentiated formulation and process package supported by a clean freedom-to-operate analysis. For the oral product, the technical risk is lower. For the IV product, the development program must address both patent scope and reproducibility of the cyclodextrin-based formulation.

How strong is the BAXDELA patent estate?

The estate is commercially stronger when it covers multiple independent layers: the delafloxacin molecule, its salt, a defined crystalline form, a specific IV solubilizer system, and treatment methods. It is weaker if protection depends primarily on broad method-of-use claims that can be carved out of a generic label.

Relative strength by product component

Component	Patent risk	Generic development difficulty
Oral tablet excipients	Low to moderate	Moderate
Delafloxacin active ingredient	High if unexpired core claims remain	High
Salt or crystalline form	Moderate to high	Moderate to high
IV cyclodextrin formulation	Moderate to high	High
Lyophilization process	Moderate	High
Method of use	Variable	Potentially manageable through labeling
Packaging and administration system	Low to moderate	Moderate

The IV product is more defensible operationally because formulation replication requires tighter control than a conventional immediate-release tablet. That advantage does not necessarily translate into durable patent exclusivity. It may instead function as a manufacturing and quality barrier.

What generic launch scenarios exist for BAXDELA?

Scenario 1: Oral generic before meaningful IV competition

This is the most straightforward entry model. A manufacturer launches a 450 mg tablet after resolving applicable Orange Book patents and regulatory exclusivity. Pricing pressure would likely be greater in outpatient and discharge markets than in inpatient IV therapy.

Scenario 2: IV generic with hospital contracting

A manufacturer launches a 300 mg vial and competes through acquisition cost, reliable supply, and pharmacy preparation economics. Hospital adoption would depend on formulary review, antimicrobial stewardship, susceptibility data, and contracting.

Scenario 3: Oral and IV portfolio launch

A combined product portfolio would allow the supplier to compete for initial treatment and step-down therapy. This model has higher development cost but improves account-level value.

Scenario 4: Reformulated outpatient product

A premixed or simplified-delivery product could target outpatient infusion centers and hospital-at-home programs. Its commercial case would depend on stability, administration time, and avoidance of pharmacy preparation.

What licensing and partnership opportunities exist?

Potential counterparties include:

• Generic pharmaceutical companies seeking a differentiated hospital antibiotic.
• Injectable specialists with lyophilization capacity.
• Excipient manufacturers supplying sulfobutyl ether beta-cyclodextrin sodium.
• Contract development and manufacturing organizations with sterile fill-finish capabilities.
• Hospital-focused distributors.
• Developers of outpatient parenteral antimicrobial therapy products.
• Regional licensees in markets where delafloxacin registration or supply remains limited.

A licensing transaction would likely value one of three assets: geographic rights, an improved IV presentation, or a lower-cost generic process. A tablet-only license would face stronger price competition. An injectable presentation with documented stability and operational advantages could support better economics.

What geographic opportunities exist for BAXDELA?

The U.S. market has the clearest regulatory framework because BAXDELA is FDA approved in both oral and IV forms. International opportunities depend on local registration, patent status, antimicrobial guidelines, and reimbursement.

Priority markets for a generic or licensed product would generally be jurisdictions with:

• High hospital antibiotic expenditure.
• Established MRSA treatment demand.
• Regulatory pathways accepting U.S. clinical and quality data.
• Local sterile manufacturing capacity.
• Strong outpatient infusion infrastructure.
• A need for IV-to-oral treatment continuity.

The manufacturing strategy should separate the oral and injectable supply chains. Oral tablets can be manufactured through conventional solid-dose facilities. The IV product requires qualified sterile manufacturing, validated lyophilization, container-closure testing, and a dependable cyclodextrin supply.

Key Takeaways

• BAXDELA uses a conventional immediate-release tablet and a more technically demanding cyclodextrin-based IV formulation.
• The most differentiated excipient is sulfobutyl ether beta-cyclodextrin sodium in the injectable product.
• Oral generic entry is technically more accessible than IV generic entry.
• The best commercial opportunities are a generic tablet, a hospital-focused IV product, and a premixed or simplified-delivery IV presentation.
• Excipient patents alone are unlikely to provide broad exclusion; practical value lies in formulation know-how, process control, and supply reliability.
• Paragraph IV risk depends on current Orange Book listings, patent expiry, salt and solid-state claims, formulation patents, and any litigation settlements.
• Fluoroquinolone safety warnings and antimicrobial stewardship policies limit unrestricted commercial expansion.
• A combined oral and IV portfolio has more strategic value than a tablet-only product because it supports treatment continuity from hospital initiation to outpatient therapy.

FAQs

Is sulfobutyl ether beta-cyclodextrin essential to BAXDELA injection?

It is a key solubilizing excipient in the approved injectable formulation. An alternative excipient system could be developed, but it would require substantial formulation, stability, quality, and regulatory work.

Can a generic manufacturer copy the BAXDELA tablet excipients?

A generic manufacturer can generally use the same functional excipient classes or suitable alternatives, subject to product quality, bioequivalence, dissolution, and regulatory requirements.

Is BAXDELA suitable for a ready-to-use infusion bag?

A ready-to-use presentation is technically possible but would require evidence for solution stability, container compatibility, particulate control, extractables and leachables, and in-use handling.

Does BAXDELA have biosimilar competition?

No. Delafloxacin is a small-molecule antibacterial, so competition would proceed through generic or other small-molecule pathways rather than the biosimilar pathway.

Which BAXDELA product has the greater commercial barrier?

The 300 mg IV product has the greater barrier because it requires sterile manufacturing, lyophilization, solubility control, reconstitution performance, and qualified cyclodextrin supply. The 450 mg tablet is more accessible to conventional generic manufacturers.

References

1. U.S. Food and Drug Administration. (2017). FDA approves new fluoroquinolone antibacterial for treatment of acute bacterial skin and skin structure infections.
2. U.S. Food and Drug Administration. (2019). BAXDELA (delafloxacin meglumine) prescribing information. Melinta Therapeutics.
3. U.S. Food and Drug Administration. (2023). BAXDELA (delafloxacin meglumine) prescribing information. Melinta Therapeutics.
4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Orange Book.